Related Experiment Video
Updated: Feb 12, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3
Hao Ke1,2, Limin Zhao1,2, Honglei Zhang1
1State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, 650223 Kunming, China.
Abstract:
Aberrant alternative splicing has been highlighted as a potential hallmark of cancer. Here, we identify TDP43 (TAR DNA-binding protein 43) as an important splicing regulator responsible for the unique splicing profile in triple-negative breast cancer (TNBC). Clinical data demonstrate that TDP43 is highly expressed in TNBC with poor prognosis. Knockdown of TDP43 inhibits tumor progression, including proliferation and metastasis, and overexpression of TDP43 promotes proliferation and malignancy of mammary epithelial cells. Deep sequencing analysis and functional experiments indicate that TDP43 alters most splicing events with splicing factor SRSF3 (serine/arginine-rich splicing factor 3), in the regulation of TNBC progression. The TDP43/SRSF3 complex controls specific splicing events, including downstream genes PAR3 and NUMB The effect of reduced metastasis and proliferation upon the knockdown of TDP43 or SRSF3 is mediated by the splicing regulation of PAR3 and NUMB exon 12, respectively. The TDP43/SRSF3 complex and downstream PAR3 isoform are potential therapeutic targets for TNBC.
Insights
Triple-negative breast cancer (TNBC) progression is regulated by TAR DNA-binding protein 43 (TDP43). Targeting the TDP43/SRSF3 complex may offer new therapeutic strategies for TNBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Aberrant alternative splicing is a recognized hallmark of cancer.
- Triple-negative breast cancer (TNBC) exhibits a unique splicing profile.
- The role of specific splicing regulators in TNBC remains to be fully elucidated.
Purpose of the Study:
- To identify key splicing regulators involved in TNBC progression.
- To investigate the functional role of TAR DNA-binding protein 43 (TDP43) in TNBC.
- To explore the therapeutic potential of targeting splicing pathways in TNBC.
Main Methods:
- Analysis of clinical TNBC data for TDP43 expression.
- In vitro knockdown and overexpression studies of TDP43 in mammary epithelial cells.
- Deep sequencing and functional assays to identify TDP43-regulated splicing events.
- Investigation of the interaction between TDP43 and serine/arginine-rich splicing factor 3 (SRSF3).
Main Results:
- TDP43 is highly expressed in TNBC and correlates with poor prognosis.
- TDP43 knockdown inhibits TNBC cell proliferation and metastasis; overexpression promotes malignancy.
- TDP43 collaborates with SRSF3 to regulate splicing events critical for TNBC progression.
- Splicing regulation of PAR3 and NUMB exon 12 by the TDP43/SRSF3 complex mediates effects on proliferation and metastasis.
Conclusions:
- TDP43 is a crucial splicing regulator in TNBC, driving tumor progression.
- The TDP43/SRSF3 complex and its downstream targets, PAR3 and NUMB, represent potential therapeutic targets for TNBC.
- Targeting this aberrant splicing axis offers a promising avenue for TNBC treatment strategies.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Coordination Number and Geometry
Coordination Compounds and Nomenclature
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Feedback Inhibition
Negative Regulator Molecules

